• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Association of nuclear beta-catenin and PD1/PDL1 expression with cancer stem niche in advanced rectal cancer

Research Project

Project/Area Number 19K07421
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 49020:Human pathology-related
Research InstitutionKitasato University

Principal Investigator

Takahashi Hiroyuki  北里大学, 医療衛生学部, 教授 (60377330)

Co-Investigator(Kenkyū-buntansha) 三枝 信  北里大学, 医学部, 教授 (00265711)
Project Period (FY) 2019-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords直腸癌 / NCRT / PD-L1 / 癌免疫監視回避機構 / 癌幹細胞ニッチ / 進行期直腸癌 / PDL1 / PD1
Outline of Research at the Start

我が国の進行期直腸癌患者数は5万人で、その予後は術前化学・放射線療法(NCRT)と外科的切除の併用療法により著しく向上したが、依然、NCRT抵抗例も認められる。申請者は先行研究によって、「進行期直腸癌のβ-カテニン依存性癌幹細胞領域(簇出部)は、PDL1陽性癌・間質細胞より形成される癌免疫不全領域(癌幹細胞ニッチ)である。NCRTにより間質のPD1/CD8陽性リンパ球が増加するが、NCRT抵抗例ではそのニッチ内のPDL1陽性癌・間質細胞も増加する。故に、NCRTと癌免疫療法併用はNCRT抵抗性直腸癌の新規治療戦略への展開が期待できる」という作業仮説を立案した。本研究はこの仮説を立証する。

Outline of Final Research Achievements

We focused on the immunological impact of PD-1/PD-L1 signaling during tumor progression in colorectal carcinoma (CRC) and its association with resistance to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal carcinoma (LAd-RC). Histopathological and immuno-histochemical analyses of 100 CRC cases (including 34 RC) without NCRT and 109 NCRT-treated LAd-RC cases were performed. A combination of stromal PD-L1+ immune cells and nuclear β-catenin+ tumor budding may contribute to tumor progression in CRC and resis-tancetoNCRTinLAd-RC, throughformation ofniche-like lesions that exhibit immune resistance and CSC properties.

Academic Significance and Societal Importance of the Research Achievements

我が国の進行期直腸癌患者数は5万人で、その予後は術前化学・放射線療法(NCRT)と外科的切除の併用療法により著しく向上したが、依然、NCRT抵抗例も認められる。NCRT抵抗性を示す進行直腸癌では、間質のPD-L1陽性免疫細胞と癌幹細胞化特性を示すニッチ様病変がNCRTへの抵抗に寄与する可能性が示されたことから、NCRTと癌免疫療法の併用はNCRT抵抗性直腸癌の新規治療戦略への展開が期待でき、今後臨床試験などで検討される価値があると考えられた。

Report

(5 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (1 results)

All 2022

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results)

  • [Journal Article] A combination of stromal <scp>PD‐L1</scp> and tumoral nuclear β‐catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma2022

    • Author(s)
      Takahashi Hiroyuki、Watanabe Hirono、Hashimura Miki、Matsumoto Toshihide、Yokoi Ako、Nakagawa Mayu、Ishibashi Yu、Ito Takashi、Ohhigata Kensuke、Saegusa Makoto
    • Journal Title

      The Journal of Pathology: Clinical Research

      Volume: 8 Issue: 5 Pages: 458-469

    • DOI

      10.1002/cjp2.285

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access

URL: 

Published: 2019-04-18   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi